In a recent move to lower prescription drug prices in the U.S., President Trump has sent letters to 17 major pharmaceutical CEOs, demanding they slash prices within 60 days. This ultimatum has sent shockwaves through the pharmaceutical industry, prompting shares in companies like Novo Nordisk to plummet. While Trump insists on urgent price reductions, many industry experts remain skeptical about the feasibility of these demands. As part of his push, Trump is also challenging drug companies to raise prices abroad instead of in the United States, placing significant pressure on both domestic and international pharmaceutical markets. The response from the industry has been mixed, with some expressing agreement with the need for change, while others criticize the approach as unrealistic.